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ARTICLE
Whole-genome sequencing of African Americans
implicates differential genetic architecture in
inflammatory bowel disease
Hari K. Somineni,1,2 Sini Nagpal,3 Suresh Venkateswaran,2 David J. Cutler,4 David T. Okou,2
Talin Haritunians,5 Claire L. Simpson,6 Ferdouse Begum,7 Lisa W. Datta,7 Antonio J. Quiros,8
Jenifer Seminerio,9 Emebet Mengesha,5 Jonathan S. Alexander,10 Robert N. Baldassano,11
Sharon Dudley-Brown,12 Raymond K. Cross,13 Themistocles Dassopoulos,14 Lee A. Denson,15
Tanvi A. Dhere,16 Heba Iskandar,16 Gerald W. Dryden,17 Jason K. Hou,18
(Author list continued on next page)

Summary
Whether or not populations diverge with respect to the genetic contribution to risk of specific complex diseases is relevant to understanding the evolution of susceptibility and origins of health disparities. Here, we describe a large-scale whole-genome sequencing study
of inflammatory bowel disease encompassing 1,774 affected individuals and 1,644 healthy control Americans with African ancestry
(African Americans). Although no new loci for inflammatory bowel disease are discovered at genome-wide significance levels, we identify numerous instances of differential effect sizes in combination with divergent allele frequencies. For example, the major effect at
PTGER4 fine maps to a single credible interval of 22 SNPs corresponding to one of four independent associations at the locus in European
ancestry individuals but with an elevated odds ratio for Crohn disease in African Americans. A rare variant aggregate analysis implicates
Ca2þ-binding neuro-immunomodulator CALB2 in ulcerative colitis. Highly significant overall overlap of common variant risk for inflammatory bowel disease susceptibility between individuals with African and European ancestries was observed, with 41 of 241 previously known lead variants replicated and overall correlations in effect sizes of 0.68 for combined inflammatory bowel disease. Nevertheless, subtle differences influence the performance of polygenic risk scores, and we show that ancestry-appropriate weights significantly
improve polygenic prediction in the highest percentiles of risk. The median amount of variance explained per locus remains the same in
African and European cohorts, providing evidence for compensation of effect sizes as allele frequencies diverge, as expected under a
highly polygenic model of disease.

Introduction
The inflammatory bowel diseases (IBDs [MIM: 604519,
266600, 191390]), Crohn disease (CD [MIM: 266600]),
and ulcerative colitis (UC [MIM: 191390]) arise in the
context of inappropriate activation of the intestinal immune system in response to an environmental trigger in
individuals who are genetically predisposed. Genome-

wide association studies (GWASs) of common and low frequency variants have so far identified 241 loci that confer
significant risk for disease susceptibility.1–3 Although inflammatory bowel disease is one of the most successfully
studied polygenic diseases with respect to identifying loci
and risk alleles, four major challenges remain: (1) missing
heritability—only a small fraction of disease liability is explained by the thus far known genetic risk factors (13% for
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Crohn disease and 8% for ulcerative colitis);2 (2) uncertainty as to the true causal genetic variants underlying
GWAS associations—as most loci span several kb to tens
of kb in length, containing credible sets that usually range
from several to hundreds of variants in tight linkage
disequilibrium (LD) having similar evidence of association;
(3) lack of molecular insights into established genetic signals—as most association signals map to non-coding regions with their mechanistic effects largely unknown;
and (4) lack of understanding on the different genetic
architectures across populations.
Genetic discoveries of inflammatory bowel disease have
been made primarily in populations of European ancestry
and utilizing genome-wide genotype data.1–3 This predominance, combined with a focus on common alleles, has left
our understanding of the role of rare variants among nonEuropean populations incomplete. To this end, we have
performed the whole-genome sequencing study of inflammatory bowel disease-affected individuals as compared to
non-inflammatory bowel disease control individuals
from over 3,600 Americans with African ancestry.
Although most GWASs are performed with genotyping arrays, whole-genome sequencing offers advantages such as
assessment of rare heterozygous effects—for example, for
type 2 diabetes4 (T2D [MIM: 125853]) and on blood metabolites5—and comprehensive assessment of non-imputed
common variants (for example, for COPD6 [MIM:
606963]), as well as mapping in the presence of high variability and short LD blocks in mixed ancestry populations
(for example, plasma lipoproteins7 and serum peptides8).

Our goals were 4-fold: first, we hypothesized that genetic
analysis of this understudied population would facilitate
new locus discovery of common variants that have not
been previously interrogated, including those that are specific to African-ancestry populations or shared across divergent populations. Second, given the high genetic diversity
in African populations, we hypothesized that rare and
potentially high-risk inflammatory bowel disease variants,
within or near protein coding genes, have yet to be identified. Third, we evaluated the potential of our genetically
diverse African American cohort to enhance fine-mapping
of credible intervals. Fourth, we evaluated the degree to
which effect sizes of GWAS variants differ across populations and assessed the impact on polygenic risk assessment
based on established inflammatory bowel disease loci.

Subjects and methods
Study samples
This was a multi-center collaborative study involving self-identified African American subjects recruited from five primary sites
and their collaborating centers across the US. These sample recruitment centers include Emory University (recruited as part of the
GENESIS study and Emory African American Inflammatory Bowel
Disease Consortium) and 12 other collaborating centers; Johns
Hopkins/Rutgers (recruited as part of the Multicenter African
American Inflammatory Bowel Disease Study) and 17 other collaborating centers; Cedars-Sinai Medical Center; Mount Sinai Medical
Center; and Washington University (recruited as part of the Centers for Common Disease Genomics network). Sample breakdown,
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along with the proportion of affected individuals versus control
individuals, per center is shown in Table S1. This study was
approved by the institutional review boards at each of the participating sites and informed consent was obtained from all the participants. Deidentified datasets including genetic data are housed
at Emory University with the approval of the local ethical board.

Library construction and whole-genome sequencing
All DNA samples investigated in this study (a total of 3,610 before
quality control [QC]) were processed and sequenced at the Broad
Institute of Harvard and MIT (Cambridge, MA) following the
same protocol. Briefly, genomic DNA (350 ng in 50 mL) extracted
from the blood of sampled participants was fragmented to a target
size of 385 bp fragments via a Covaris Focused-ultrasonicator. Fragmented DNA was subjected to further size selection via a SPRI
cleanup. Libraries were then constructed with kits commercially
available from KAPA Biosystems (KAPA Hyper Prep without amplification module, product KK8505) and with palindromic forked
adapters with unique 8-base index sequences embedded within
the adaptor (purchased from Roche). Completed libraries were
quantified with quantitative PCR (kit purchased from KAPA Biosystems), normalized to 2.2 nM, and were pooled into 24-plexes.
Sample pools were combined with HiSeqX Cluster Amp Reagents
EPX1, EPX2, and EPX3, and cluster generation was performed
with the Illumina cBot according to the manufacturer’s protocol
(Illumina). DNA libraries were sequenced with the HiSeqX
sequencing system utilizing sequencing-by-synthesis kits to produce 151 bp paired-end reads. Because library amplification by
PCR introduces substantial bias, we sequenced our samples by using the PCR-free protocol. Output from Illumina software was processed by the Picard data-processing pipeline to yield CRAM files
containing demultiplexed, aggregated aligned reads.

Data processing and variant calling
The sequence reads from each sample were aligned to human
reference genome build hg38 (GRCh38 assembly). Each sample
was sequenced to an average depth of 303. Variants were joint
called across 3,610 samples via the Genome Analysis Toolkit
(GATK) Best Practices for germline variants9 and were annotated
via our in-house Bystro10 software. Our initial output, VCF file,
had data for 3,610 samples and about 145 million variants, both
single nucleotide polymorphisms (SNPs) and short insertions
and deletions (INDELs), which was then subjected to both sample
and variant QC as outlined below.
Sample QC and filtering
Using a subset of 1.4 million LD-independent (r2 < 0.1), high
frequency (minor allele frequency [MAF] > 1%) variants, we performed sample QC to identify individuals with discordant sex information, low call rates (<95%), and unexpected relatedness.
Briefly, we tested for agreement between X/Y genotypes and ascertained sex by using PLINK11 and excluded samples with discordant gender from subsequent analysis. Per-sample missingness
rate was calculated via the –missing option, and individuals with
more than 5% missing genotypes were removed from further analysis. To identify duplicated or related individuals, by using a subset
of 1.4 million LD-independent (r2 < 0.1), high frequency (MAF >
1%) variants, we first calculated identity by state (IBS) for each pair
of individuals, and then we estimated the degree of recent shared
ancestry for each pair of individuals (identity by descent [IBD];
whose values range from 0 to 1) again by using PLINK.11 For duplicated samples (IBD > 0.5), we removed one of the samples either

with low quality metrics at any of the QC steps or at random
when both samples were of high quality. For pairs of individuals
that appeared to be genetically related—first-degree relatives
(IBD ¼ 0.5) or second-degree relatives (IBD ¼ 0.25)—one individual from each pair was removed from subsequent analyses. Similarly, two individuals from parent-offspring trios were dropped.
While removing related samples, preference was given to keep
the affected individual or the sample with high overall quality.
Our final analytical set only included samples where the
maximum relatedness between any pair of individuals is less
than a second-degree relative. Collectively, these QC procedures
resulted in the removal of 35 samples with sex discrepancies, 42
samples with missing variant data, and 122 duplicated samples
or related individuals.
In addition, using the observed genotypes across the entire
genome, we estimated and removed samples with outlying
(defined as 53 standard deviations from the mean) heterozygotic/homozygotic changes (n ¼ 44), theta (n ¼ 12), exonic theta
(n ¼ 13), exonic transition/transversion (n ¼ 1), silent/replacement (n ¼ 1), silent transition/transversion (n ¼ 1), and replacement transition/transversion (n ¼ 1) ratios. We also removed three
samples with missing phenotypes. Collectively, after all these sample QC procedures, a total of 192 unique samples were excluded
from subsequent analyses.
Variant QC and filtering
After the removal of samples from above, we then filtered out variants genotyped in <95% of the samples (missingness > 5%) and
those that showed a significant deviation from Hardy-Weinberg
equilibrium in control individuals (p < 1 3 109). These procedures resulted in a final dataset of 3,418 samples and 93.4 million
variants that include both SNPs and INDELs. In addition, we
applied RepeatMasker12 to mask variants from repetitive and low
complexity regions of the genome. For some common variant association analysis, we also included the pre-masked dataset in order to obtain summary statistics for some of the lead variants from
the previously known disease loci (identified via populations of
predominantly European ancestry) that were masked by the RepeatMasker program.
Principal-component analysis of sequence data
After excluding samples and variants with low quality, principalcomponent analysis of the whole-genome sequencing dataset
was performed with EIGENSTRAT.13 Principal components were
computed on the basis of a pruned version of the dataset consisting of 1.4 million LD-independent (r2 < 0.1), high frequency
(MAF > 1%) variants. The first five principal components (based
on the inspection of the scree plot) were included as covariates
to control for population stratification within the whole-genomes
dataset for all analyses (Figure S1).
Single-variant association testing of sequence data
We used a logistic regression model to test for association at each
individual variant with the first five principal components of the
genotype matrix included as covariates. Variants were tested separately for association with Crohn disease, ulcerative colitis, and inflammatory bowel disease (Crohn disease and ulcerative colitis
together with inflammatory bowel disease-type unknown
[IBDU]). We defined common variants as those that are present
in at least 1% of the general African population from gnomAD
and have an observed MAF > 1% in this dataset, yielding 14.9
million variants (pre-masked; 7 million variants in the postmasked dataset). The genomic control (lGC) values for these individual analyses of common variants ranged from 1.02 to 1.04,
indicating little or no inflation or deflation due to population
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stratification. We defined rare variants as those that are either absent or present at an MAF of < 0.1% in the general African population from gnomAD. With these criteria, we observed 64.2
million rare variants in our dataset, and the genomic control
(lGC) values for these individual analyses of rare variants ranged
from 0.61 to 0.84, indicating deflation due to the limited number
of rare alleles in the dataset.
Known association in ADCY7
Adenylate cyclase 7 (ADCY7 [MIM: 600385]) has recently been
implicated in ulcerative colitis in European populations; using a
low-pass whole-genome sequenced case-control cohort in
conjunction with well-imputed newly genotyped and pre-existing
GWAS case-control datasets of European ancestry and affected individuals and non-inflammatory bowel disease control individuals
from the UK Biobank, Luo et al.14 identified a low-frequency (MAF
¼ 0.006), missense variant, rs78534766, in ADCY7 in association
with an increased risk of ulcerative colitis. In fact, rs78534766 is
the largest effect allele that was identified to date for ulcerative colitis (odds ratio [OR] ¼ 2.19; p ¼ 9 3 1012). However, although
there is no evidence of association for ulcerative colitis in our
study, we noticed an effect trending in the opposite direction
(OR ¼ 0.46; p ¼ 0.47). The effect allele was seen in seven control
individuals (MAF ¼ 0.002) and one affected individual with ulcerative colitis (and four affected individuals with Crohn disease) in
our whole-genome sequencing dataset: this could in part be due
to the limited sample size of our dataset, fueled by the rarity of
this allele, rs78534766, in general African populations (MAF in
gnomAD v3 ¼ 0.00098).
Power analysis
For power calculations, we assumed that disease prevalence
(0.19% for Crohn disease and 0.20% for ulcerative colitis) and effect sizes are homogeneous across ancestries. We converted population frequencies (reported in African populations from gnomAD) and odds ratios (reported in the latest meta-analysis of
European descent individuals3) to affected and control individual
frequencies and calculated power of our whole-genomes cohort to
detect previously known disease loci at p < 5 3 108 or p < 0.05 as
a function of the MAF and the genotype relative risk of the variant
under an additive model.
Aggregate rare-variant association testing
Using the optimal sequence kernel association test (SKAT-O),15 we
performed gene-wide aggregation analyses to detect aggregate association of rare, likely deleterious (combined annotation dependent
depletion (CADD) > 15) variants with the three traits. For aggregate
tests, we selected all rare, likely deleterious (CADD > 15) variants
(n ¼ 1.5 million) across the genome and assigned them to the nearest gene. We then assessed the association of each gene with a
collection of rare, likely deleterious variants in a SKAT-O model
implemented in the R package ‘‘SKAT.’’ To interpret statistical significance, we applied experimental-wide, Bonferroni-corrected significance threshold of p < 2.2 3 106 ¼ 0.05/22,521.

GWAS genotype data, QC, imputation, and association
testing
Sample information, genotype data, and the application of QC
procedures for the two existing GWAS cohorts considered in the
current study were described extensively elsewhere.16 Briefly,
genome-wide genotype data from non-overlapping African American affected individuals and matched control individuals generated with either the Illumina Omni (398 with Crohn disease,
238 with ulcerative colitis, and 1,551 control individuals) or the

Affymetrix Axiom Genome-Wide AFR 1 World Array (451 with
Crohn disease, 186 with ulcerative colitis, and 3,038 control individuals) SNP chips were considered for replicative evidence. Sample and variant QC, determination of principal components, and
removal of outliers was done as described in the original paper.16
Both datasets were lifted from human reference build hg19 to
hg38 via liftOver.17
Imputation
We phased the whole-genome sequences described above (n ¼
3,418; after QC) with Eagle v2.418 to create a reference panel.
These pre-phased whole-genome sequences with MAF > 0.5%
were imputed into each GWAS dataset, separately, via minimac3
software.19 By design, all the sequenced individuals have African
descent and about half of these are inflammatory bowel diseaseaffected individuals, thereby enriching the reference panel for African-specific alleles that increase or decrease inflammatory bowel
disease risk.
Common variant association testing for replicative evidence
After removing samples that were directly sequenced in the discovery phase, genotyped and imputed variants with INFO score
> 0.6 were tested for association with Crohn disease, ulcerative colitis, and inflammatory bowel disease, separately, within each
GWAS case-control dataset via SNPTEST 2.5.2,20 performing an additive frequentist association test conditioned on the first ten principal components. For sites that were present in both datasets and
passed our QC filters, we performed meta-analysis by using
META.21–23 For a common variant with p < 5 3 108 in the discovery cohort to be inferred to be associated with a trait, it had to have
a directionally consistent effect and demonstrate at least a nominal evidence of association (p < 0.05) in the meta-analysis of the
two GWAS datasets. At the 5p13.1 locus near Prostaglandin E Receptor 4 (PTGER4 [MIM: 601586]), the previously defined peak
SNP rs7711427 was initially relegated to a ‘‘sub-PASS’’ tranche during GATK’s automated analysis, but closer inspection revealed that
the reason for exclusion was an excess of heterozygotes in affected
individuals. As this is a well-characterized disease-associated
variant and strong disease alleles will give rise to excess heterozygosity in affected individuals, we elected to ‘‘rescue’’ this allele.
Because this site is in complete LD (r2 ¼ 1) with several other sites,
no conclusions are altered, but we retain rs7711427 to facilitate
comparison with published results.

Genetic risk score calculation
Assessment of precision (equivalent to predicted prevalence in a
percentile of risk) is sensitive to the ratio of affected individuals
to control individuals, so it cannot be conducted directly on the
whole-genome sequencing cohort. In order to directly contrast
accuracy in a population with a maximal inflammatory bowel disease prevalence of 1%, we thus generated 150,000 pseudo-controls given expected genotype frequencies observed in our 1,644
African American whole-genome sequenced control individuals.
Rather than using an external reference database of allele frequencies in African Americans, since these are known to be heterogeneous due to varying degrees of admixture, we used the control
estimates from our whole-genome sequencing for internal consistency and simply generated random genotypes according to
Hardy-Weinberg expectations. These were computed for 215 of
the 241 known loci that were present in both the African American pseudo-controls cohort and UK Biobank. In the pseudo-controls, we combined genotypes between loci independently to
minimize LD within the pseudo-control population. Note that
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we only use the lead SNPs and, as a result, make no attempt to capture independent secondary signals at each locus24 or to disentangle the combined effects of multiple interacting sites in high
LD.25 Instead, we simply acknowledge that some of the observed
differential effect sizes may be due to the combined influence of
secondary sites in LD or epistasis. By ignoring neighboring sites
with main effects, we are certainly under-representing the total
amount of variance explained per locus25–28 but eliminating any
influence of these effects on the derivation of pseudo-controls.
In the absence of a very large external dataset of African ancestry
inflammatory bowel disease genotypes, this is currently the leastbiased approach to estimating per-locus effects in polygenic risk
score (PRS) estimation, but it should be recognized that there
may be other systemic biases to the use of pseudo-controls that
contribute to the ancestry-specific assessments. To confirm that
long-range LD is also not biasing the analysis, we computed the
pairwise matrix of LD among all lead SNPs in our whole-genome
sequenced ‘‘real’’ control individuals. Reflecting the fact that the
SNPs are dispersed across the genome, only 6 of 23,005 comparisons were significant at the Bonferroni adjusted threshold of
2 3 106 in this observed dataset, in each case generating squared
genotype correlations (r2) between 2% and 7%, with an overall
average r2 of just 0.07%. By design, there was no observed significant LD among the variants in the pseudo-controls. Consequently, bias introduced by LD among the lead SNPs appears to
be measurably small in the African American pseudo-controls dataset, which has 1,774 inflammatory bowel disease affected individuals and 150,000 pseudo-controls. We similarly generated a
UK Biobank dataset of the same size by down-sampling to the
same case-control ratio; in this case, actual genotypes were used
because UK Biobank is sufficiently large.
Next, to compute the genetic risk score, we divided each of the
five sets of African American pseudo-controls and UK Biobank into
a training set with 70% samples (1,242 affected individuals,
105,000 pseudo-controls) and test sets with the remaining 30%
samples (532 affected individuals, 45,000 pseudo-controls). We
used the 70% training datasets to estimate effect sizes both on
the lnOR scale as well as the liability scale (these data were also
used to estimate proportion of variance explained [PVE]). Using
these estimated effect sizes at the most significant variants in the
215 of the 241 known loci that were present in both the African
American pseudo-controls cohort and UK Biobank, we derived
weighted PRSs in the withheld 30% datasets. Furthermore, for
each PRS, the prevalence of inflammatory bowel disease, with
standard error determined from the five test sets, was computed
at each percentile bin on both the liability scale and lnOR scale.
The proportion of variance explained by PRS was computed by
determining the Negelkerke’s R-square via the ‘‘lrm’’ function
from the ‘‘rms’’ package in R.29

Liability scale modeling
Liability effects were measured by assuming an underlying normal
distribution (mean 0, variance 1) of liability representing disease
status. Affected individuals are assumed to lie above a certain
threshold of this continuous distribution. This threshold (Z score
on x axis) is determined by computing the inverse of the cumulative normal function of the assumed prevalence of the disease.
Assuming an upper limit for the prevalence of all inflammatory
bowel diseases as 1%, odds ratios determined from logistic
regression as the true odds ratios, and using the allele frequencies
in control individuals within the study, we determined the addi-

tive effects on liability as follows:30,31 the displacement of each
genotype threshold from the overall population threshold as
[2.326-norminv(1-penetrance)] where the penetrance of the genotype is the overall prevalence (1%) multiplied by the ratio of the
genotype between affected individuals and overall. The mean
displacement was computed as the sum of the products of the
three genotype displacements weighted by the genotype frequencies in the overall sample, which allows computation of the
central displacement of each genotype by subtraction of the
mean displacement. The liability alpha1 of the larger effect genotype is then [p*central displacement_AAþq*central displacement_Aa] where p is the frequency of the minor allele A and q is the frequency of the major allele a. Similarly, the liability alpha2 of the
alternate allele is [p*central displacement_Aaþq*central displacement_aa]. The total variance explained by the locus on the liability
scale is 2*p*alpha12 þ2*q*alpha22. The polygenic risk score for an
individual is the sum of the liabilities of the relevant genotypes,
namely 2*alpha1, alpha1þalpha2, or 2*alpha2.

Results
Common variant associations in African Americans
After QC (see subjects and methods) and principal-component analysis (Figure S1) of our deeply sequenced whole genomes (median coverage of 303), we present analyses of a
total of 3,418 subjects: 1,774 affected individuals (1,335
with Crohn disease, 407 with ulcerative colitis, and 32
with IBDU) and 1,644 non-inflammatory bowel disease control individuals (Table S1) at 93 million variants that
comprise both SNPs and short INDELs. These data include
14.9 million common variants (MAF > 1%), 13.9 million
low-frequency variants (0.1% < MAF < 1%), and 64.2
million rare variants (MAF < 0.1%). First, we used singlevariant analyses to test each variant, regardless of allele frequency, for association with Crohn disease, ulcerative colitis,
and inflammatory bowel disease (Crohn disease and ulcerative colitis together with IBDU), separately, in a logistic
regression framework conditioned on the first five principal
components (see subjects and methods). Following these
‘‘discovery’’ analyses of whole-genome sequence data, we
sought replication of the obtained results at common variants in an independent cohort of African American affected
individuals and control individuals that were previously
genotyped with Axiom or Omni genome-wide SNP arrays16 (subjects and methods; Table S1). We imputed our
whole-genome sequences into these two (Axiom and
Omni) existing GWAS datasets, thereby enriching the panel
for inflammatory bowel disease risk alleles, and performed
case-control association testing by using a logistic regression
model, separately, within each dataset. Results from the
meta-analysis of these two GWAS datasets served as our replicative evidence for common variation.
With a standard GWAS significance threshold of p < 5 3
108 in the discovery cohort and at least nominal (and directionally consistent) evidence of association (p < 0.05) in
the replication cohort, we identified 22 common variants
at a locus proximal to PTGER4 (260 kb) on chromosome
5p, previously discovered in cohorts of European descent,

The American Journal of Human Genetics 108, 431–445, March 4, 2021 435

Figure 1. Regional plots of the PTGER4
region in the discovery whole-genome
sequence data
Crohn disease (top); ulcerative colitis
(middle); inflammatory bowel disease
(bottom). Dashed red lines indicate
genome-wide significance (p ¼ 5 3 108).
Variants are color coded to show linkage
disequilibrium structure relative to a
variant, rs6896969, that showed the strongest association with Crohn disease in African Americans in our previous GWAS.16

associated with a decreased risk of Crohn disease (Figure 1
and Table S2). All 22 variants were in complete LD with
each other (r2 ¼ 1). Following our previous report of suggestive evidence of association at this locus for Crohn disease in African Americans,16 here we present the first evidence of standard (GWAS) genome-wide significance.

Consistent with being a Crohn disease-specific locus, the disease-associated alleles demonstrated strong
effect sizes for Crohn disease (OR ¼
0.74; p < 5 3 108) but not ulcerative
colitis (OR ¼ 0.91; p ¼ 0.25; Figure 1)
despite being directionally consistent
to both. Further, of all the ancestrally
divergent populations studied thus
far, the strongest effect on Crohn disease at these variants was observed in
our
African
American
cohort
(Figure S2).
A protective role in Crohn disease
of PTGER4 locus minor alleles was
initially discovered in populations
of European ancestry,32 and 2,819
common variants at the locus had
genome-wide significant association.
Using conditional stepwise regression to perform fine-mapping, Huang
et al. further refined this region to a
subset of 189 credible variants representing four independent signals
that are more likely to be causal to
Crohn disease24 (Figure S3). The 22variant African American signal precisely captures the known primary
peak (signal 1) of association in European populations (MAF in African
American Crohn disease-affected individuals ¼ 0.32 and control individuals ¼ 0.39; MAF in European Crohn
disease-affected individuals ¼ 0.33
and control individuals ¼ 0.39); there
is no evidence for an association at
signal 2 but nominal evidence at signals 3 and 4. The 22 Crohn diseaseassociated variants that we detected at this locus in African
Americans were in high LD with the strongest signal
(signal 1) comprising two potentially causal variants—
rs7711427 and rs397897680—from the fine-mapping
analysis of European populations32 (Figure S4). We note
that rs397897680 has since been merged with rs5867512,
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Figure 2. QQ plot of rare-variant gene-level association analysis
of ulcerative colitis
Observed negative log p values are from the SKAT-O test.15

while rs7711427 was excluded during our initial QC procedure (see subjects and methods). Despite a prior
report30 of an expression quantitative trait effect on
PTGER4 expression in lymphoblastoid cells in European
individuals, the African American disease-associated alleles
appear to be located distal to that signal as well as the major eQTL interval reported on the Blood eQTL browser.
Experimental manipulation of epithelial cells supports a
role for prostaglandin signaling promoting intestinal
wound healing during inflammatory bowel disease,33 but
it remains to be established whether PTGER4 is the target
of the primary GWAS signal that lies in a gene desert 250
kb from a cluster of candidate genes and whether expression is affected in diseased epithelial cells.
Rare-variant associations in African Americans
With the sequencing data, we next assessed the contribution of rare variants (MAF < 0.1%) to inflammatory bowel
disease. Our data was comprised of 64.2 million rare variants that include many alleles that were not genotyped
or imputed in previous GWASs of inflammatory bowel diseases. Because our single-variant analyses at rare variants
yielded deflated summary statistics (Figure S5), we performed aggregate analyses by selecting all rare, likely deleterious (CADD > 15) variants across the genome and assigning them to the nearest gene. In total, 1.5 million
such variants were assigned to 22,521 genes with an
average of 68 variants per gene (range ¼ 1–3,593). Using
the SKAT-O approach,15 we then tested whether any of

these gene sets with a collection of rare, likely deleterious
variants have an aggregate association with inflammatory
bowel disease, Crohn disease, or ulcerative colitis. To interpret statistical significance, we applied a Bonferroni-corrected significance threshold of pSKAT < 2.2 3 106 (0.05
corrected for 22,521 tests).
Using this strategy, we implicate variants in the vicinity
of Calbindin 2 (CALB2 [MIM: 114051]) in ulcerative colitis.
We detected an aggregate association of 35 rare, likely deleterious, heterozygous variants within or near CALB2 with
ulcerative colitis (pSKAT ¼ 1.61 3 106; Figure 2 and Table
S3). Half of these variants were observed more frequently
in affected individuals with ulcerative colitis compared to
control individuals, while the other half were seen less
frequently, representing a typical SKAT type of signal.
Among the 35 variants that collectively contributed to
this aggregate signal, many are absent in European (nonFinnish) populations in the gnomAD v3 release34 (15 as
opposed to only 4 variants that were never seen before in
African populations) despite a 0.6-fold larger European
effective sample size, including an African-specific intronic
variant, rs200083611, with a nominal evidence of association for increased risk of ulcerative colitis, showing an MAF
of 0.009 in affected individuals and 0.0003 in control
individuals (p ¼ 0.001; OR ¼ 30.5 from single variant association analysis). However, given the high-risk but weak
evidence of association at rs200083611, it appears that
the CALB2 gene-wide signal was driven by multiple additional rare variants.
This CALB2 signal was approximately 3 Mb away
from, and independent of, the nearby common
variant, rs1728785 (intronic region of ZFP90 [MIM:
609451]), that has an established association for ulcerative
colitis,2,14,35 indicating that these rare variant associations
represent unique effects. CALB2 encodes an intracellular
calcium-binding protein, calbindin 2 (also known as calretinin), that plays an important role in neuronal physiology
and the maintenance of Ca2þ intracellular homeostasis.
CALB2 has a common expression pattern in both the central and peripheral nervous systems. It has high expression
in brain and intermediate expression in sigmoid and transverse colon. The absence of CALB2 in nerve fibers in colon
is a widely used marker for Hirschsprung disease36,37
(HSCR1 [MIM: 142623]), whereas elevated expression of
CALB2 has been reported as a hallmark of rapidly proliferating cancerous cell lines, including in colorectal cancer
cell lines.38 Hirschsprung disease shares many of the clinical features with inflammatory bowel disease, where the
latter is more commonly reported in affected individuals
who had surgical treatment for Hirschsprung disease.39
Conversely, long-standing inflammatory bowel disease is
an established risk factor for colorectal cancer.40,41 Given
the intricate relationship of inflammatory bowel disease
with these companion diseases, our implication of Hirschsprung disease- and colorectal cancer-associated CALB2 in
ulcerative colitis makes this signal worthy of experimental
validation.
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Figure 3. Comparison of effect sizes across populations
(A) Statistical power of the discovery whole-genome sequencing dataset to replicate previously known variants at p < 0.05. The known
variants that showed an association (p < 0.05) with Crohn disease, ulcerative colitis, or inflammatory bowel disease in African Americans
are colored to denote their p value of association.
(B–D) Comparison of effect sizes at known variants in African Americans and Europeans. Each variant is colored to denote the p value of
association for Crohn disease (B), ulcerative colitis (C), or inflammatory bowel disease (D) in African Americans from the discovery
whole-genome sequencing cohort. The red line shows the linear regression fit to indicate the general trend. Significance and goodness-of-fit are shown. ADCY7 was not included while computing goodness-of-fit in (C) (see subjects and methods).

Genetic landscape at the established disease loci
between African Americans and Europeans
With our whole-genomes data, we next assessed whether
the genetic landscape at established inflammatory bowel
disease risk loci is shared between populations of European and African descent and whether trans-ethnic
comparative analysis can be leveraged to further refine established GWAS signals. Of the 241 lead variants from the
thus far established loci from the recent meta-analyses of
cohorts of European descent3 (GWAS catalog), in addition
to replicating the known PTGER4 locus at p < 5 3 108,
we replicated 41 lead variants for association with inflammatory bowel disease, Crohn disease, or ulcerative colitis
(see Table S4 for all lead variant data). Assuming Crohn
disease and ulcerative colitis prevalence of 0.19% and
0.20%, respectively, and no ascertainment bias, our

whole-genomes cohort was powered to replicate 42 of
the known loci at p < 0.05 (see subjects and methods;
Figure 3), matching the number of associations actually
observed. Despite limited statistical evidence of association at many of the known loci as a result of the size of
our African American cohort, we noted a strong concordance in the direction of effects (73%, p ¼ 2.05 3 1012
for inflammatory bowel disease; 69%, p ¼ 1.26 3 108
for Crohn disease; and 64%, p ¼ 2.48 3 105 for ulcerative colitis; sign test) and a strikingly positive correlation
in effect sizes between European and African populations
(R ¼ 0.68, p < 2.2 3 1016 for inflammatory bowel disease; R ¼ 0.63, p < 2.2 3 1016 for Crohn disease; and
R ¼ 0.43, p ¼ 3.0 3 109 for ulcerative colitis), further
supporting the previous notion that the genetic risk of inflammatory bowel diseases conferred by common variants
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Figure 4. Median proportion of variance
explained by inflammatory bowel disease
loci in African Americans and Europeans
via effects estimated from the two populations
(A and B) Median proportion of variance
explained (PVE) by the known loci (n ¼
215 SNPs) assessed via allele frequencies
and effect sizes estimated in African American pseudo-controls and UK Biobank datasets measured on lnOR and liability scales
across five discovery sets. PVE is computed
as 2p.q.ln(OR)2 on lnOR scale (A);
2.p.alpha12 þ 2.q.alpha22, where alpha1
and alpha2 are liability estimates on liability scale (B).
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is, to a great extent, shared across divergent populations
(Figure 3).
Despite strong effect-size correlations, subtle differences
in allele frequency or the magnitude of effects at the established disease loci may reveal differential genetic architectures underlying inflammatory bowel disease between the
two populations. Given that our African American dataset
is at least one order of magnitude smaller than the existing
European datasets, in order to contrast effect estimates
directly between the two populations, and assuming a
maximal underlying inflammatory bowel disease prevalence of up to 1%, we generated 150,000 pseudo-controls
from the observed genotypes in our whole-genome
sequenced control individuals (n ¼ 1,644) to contrast
against the 1,774 inflammatory bowel disease-affected individuals. We refer to this from here on as African American pseudo-controls cohort (with 1,774 affected individuals and 150,000 pseudo-controls). For the European
counterpart, we took advantage of the UK Biobank (all
the observed genotypes were used because the UK Biobank
is sufficiently large, 1,774 individuals with inflammatory
bowel disease and 150,000 non-inflammatory bowel disease control individuals; see subjects and methods). For
both the African American pseudo-controls cohort and
UK Biobank, we generated five random subsets retaining
70% of the samples (1,242 affected individuals and
105,000 pseudo-controls) as discovery sets for estimating
effect sizes. In a comparative analysis of effects (natural
log transformed odds ratios [lnOR]) at the known loci,
69% of the African American estimates are within the
95% confidence interval of UK Biobank estimates (and
75% vice versa), implying general similarity of odds ratios.
The distributions of the lnOR are significantly biased toward higher absolute values in African Americans (p ¼
0.01, two-tailed paired sample t test, n ¼ 215 SNPs) and
are highly correlated with those generated directly from
the whole-genome sequencing study and shown in Figure 3
(mean r ¼ 0.88). Scores generated directly from the discovery cohort may also bias the estimation (although note

that we are only considering lead SNP effects previously
identified in predominantly European ancestry studies),
but considered together, the two approaches increase the
robustness of our findings. The correlation between the
odds ratio estimates from the de Lange et al. meta-analysis3 and the inflammatory bowel disease estimates in
five UK Biobank iterations is just 0.77 on average, which
is greater than those estimated between the African American pseudo-controls and UK Biobank (0.48) or the direct
African American whole-genome sequencing GWAS and
European meta-analysis (0.68). Thus, generation of
pseudo-controls introduces minimal bias.
Since allele frequencies co-vary with odds ratios, explaining approximately 6.1% (mean R2 across five sets) of
the difference in odds ratio between the populations
(Figure S6), we also computed effect sizes on the liability
scale (see subjects and methods), which is not a function
of allele frequency. These estimates are also biased slightly
upward in African Americans (mean R2 ¼ 3.1%; Figure S6).
The median percent variance explained per locus is very
similar whether on the lnOR or liability scales in the two
populations (Figure 4). Nevertheless, we estimate that
given either the European or African allele frequencies,
typically 40%–50% more variance would be explained
with the observed African American effect sizes. Reciprocally, for either distribution of effect sizes, the European
allele frequencies lead to 1.35–1.45 times greater variance
explained. Collectively, these observations suggest that
compensatory differences in both effect sizes and allele frequencies contribute to divergence in inflammatory bowel
disease risk between European and African populations.
The effect size differences may be due to local ancestry effects of LD with secondary associations at loci and to global
interactions with the total genetic background.
Variance in disease liability in African Americans and
Europeans
For 215 of the 241 known loci that we had data for in both
the African American pseudo-controls cohort and UK
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A

Figure 5. Comparison of proportion of
variance explained (PVE) per locus in African Americans and Europeans at known
loci (n ¼ 215 SNPs) via effects estimated
on the lnOR and liability scales
(A) PVE is computed as 2p.q.ln(OR)2.
(B) PVE is computed as 2.p.alpha12 þ
2.q.alpha22, where alpha1 and alpha2 are liability scale estimates.

B

Biobank, we estimated the mean PVE by each locus from
five discovery subsets in both lnOR and liability scale,
and this is illustrated in Figure 5. While the two large effect
European Crohn disease-associated alleles at IL23R and
NOD2 explained 4.58% and 1.08% PVE on lnOR scale
(0.59% and 0.15% on liability scale) in the UK Biobank
cohort, they only accounted for 1.02% and 0.24%
(0.13% and 0.03% on liability scale) in the African American pseudo-controls cohort, respectively. Conversely, the
risk allele at rs3764147 (genes in the region include
LACC1 [MIM: 613409] and CCDC122 [MIM: 613408])
that depicted suggestive evidence of association (p ¼
1.2 3 107) in our discovery African American cohort accounted for 2.71% PVE in the African American pseudocontrols cohort, while it only explained 0.40% in Europeans (0.37% and 0.05% on liability scale, respectively;
Figure 5). Similarly, the PTGER4 signal that we detected
at p < 5 3 108 in our whole-genome sequencing
analysis explained 3.35% of PVE in African Americans
versus 0.93% in Europeans (0.45% and 0.12% on liability
scale, respectively).
Transferability of polygenic risk scores across
populations
These subtle differences at each individual locus when
combined across a genome-wide feature set, for example
while deriving polygenic risk predictors for a common
complex disease, lead to significant biases in populations
distinct from the discovery samples.42,43 In order to
directly contrast accuracy in a population with inflammatory bowel disease prevalence of up to 1%, we utilized the
effects estimated from our five discovery sets generated
from 70% of 1,774 affected individuals and 150,000
pseudo-controls and used the remaining 30% of the withheld samples from each of the five sets for computing PRSs
at 215 of the 241 known loci that we had data for in both
the African American pseudo-controls cohort and UK Biobank. Strikingly, after 5-fold cross validation, the African
American-estimated betas gave a 7-fold elevation of the

top percentile in African Americans
but underestimated risk in the UK
Biobank.
Similar
results
were
observed with liability scale estimates
(Figure 6) and lnOR’s (Figure S7). On
the other hand, the UK Biobank-estimated betas applied to UK Biobank
samples yielded 3-fold elevation in
the top percentile and performed better than the African
American beta estimates applied to the UK Biobank. Specifically, for PRSs computed in African Americans, the prevalence in the top percentile was 7.4% (mean PVE by PRS
from five test sets: R2 ¼ 0.026) with African American summary statistics, 2.5% (mean PVE: R2 ¼ 0.011) with UK Biobank summary statistics, and 2.9% (mean PVE: R2 ¼ 0.010)
with summary statistics obtained from the largest GWAS
meta-analysis of European individuals.3 For PRSs
computed in UK Biobank individuals, the prevalence in
the top percentile was 2.8% (mean PVE: R2 ¼ 0.009) with
African American summary statistics, 3.0% (mean PVE:
R2 ¼ 0.019) with UK Biobank summary statistics, and
3.8% (mean R2 ¼ 0.027) with summary statistics from
GWAS meta-analysis of European individuals (Figure S7).
Although there may be systemic biases in the use of
pseudo-controls (see subjects and methods), these results
confirm and extend recent observations concerning
the propensity for PRS distributions to differ between
Europeans and Africans based on discovery ancestry
group.42,44,45
In order to further validate these conclusions, we also
stress-tested the PRS estimation by a series of perturbations
summarized in Figure S8, all of which retain the core result
that using African American-estimated weights improves
PRS discrimination. Substituting lnOR estimated directly
from the whole-genome sequencing (Figures S8A–S8D),
the overall PVE actually increases to 4.5% in the African
ancestry samples, although the prevalence in the upper
percentile is reduced a percentage point, while there is little impact on the European ancestry evaluation. Substitution of European meta-analysis effect-size estimates for
ones generated from the UK Biobank also improves the
PVE in Europeans (but not Africans), most likely because
the down-sampling procedure—like the pseudo-control
generation—uses a reduced sample size in the estimation.
Furthermore, we removed various large-effect SNPs to evaluate whether they may be driving the improved performance. Figures S8E and S8F show that removing four
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Figure 6. Polygenic risk scores (PRSs) in
African Americans and Europeans as a
function of different discovery ancestry
groups
PRSs in African Americans and UK Biobank
individuals derived via 215 of the known
disease SNPs and liability scale effects estimated from the African American discovery cohort (AA_liability, red) or the UK
Biobank discovery cohort (UKBB_liability,
green).
(A and B) Prevalence of IBD (%) versus
percentile of PRS in each cohort.
(C and D) Mean proportion of variance explained (PVE) by each PRS. Standard error
bars are from five test sets.

variants with MAF < 0.02, three with OR > 1.2, has just a
small impact on the prevalence-risk score relationship, as
does removing the five variants with the largest absolute
value of the OR, three of which have protective minor
alleles.

weaker evidence of association, supporting the potential
of trans-ethnic meta-analysis as a means to further
improve the resolution of credible sets that had been constructed with a homogeneous population.

Potential of population diversity to improve finemapping
Analysis of genetic data from divergent populations is
thought to improve fine-mapping resolution of causal variants by leveraging trans-ethnic differences in LD, effect
sizes, and allele frequencies. The fixed-effects meta-analysis of our African American whole-genome sequence
data with summary statistics from European individuals2
at the previously fine-mapped (to 95% credible sets)
loci31 showed marked improvement in fine-mapping resolution. Of the 3,529 credible variants from 94 loci that we
meta-analyzed, 552 variants (16%) from 40 signals showed
a change in p value of association with the previously assigned phenotype (inflammatory bowel disease, Crohn
disease, or ulcerative colitis) by a factor of at least 10 (up
to 100,000; Table S5). Of these, we noted an improvement
in the strength of the association for 320 variants, while
weaker association was observed for 232 variants. For
instance, of the three credible variants that constituted a
95% credible set near Interleukin 23 Receptor (IL23R
[MIM: 607562]; HD 7, signal 1 in Libioulle et al.32), we
noted an improvement in association at the variant with
the highest posterior probability (PP) of being causal (PP
¼ 0.49). Conversely, a weaker association was observed
for one (PP ¼ 0.26) of the three 95% credible set-variants
near SBNO2 (MIM: 615729). Similarly, 98 of the analyzed
120 credible variants near IRGM (MIM: 608212) (HD 67,
signal 1, 95% credible size ¼ 145 variants) and 102
(including a variant with PP ¼ 0.58) of the analyzed 355
credible variants near DOCK3 (MIM: 603123) (HD 50,
signal 1, 95% credible size ¼ 437 variants) demonstrated

Discussion
To further resolve the genetic architecture of inflammatory bowel disease and better define the differential genetic structure of the disease across divergent ancestries,
we have performed the whole-genome sequencing analyses that include many alleles that were not previously
examined in a population that remains very significantly
understudied. Similar to the findings of a whole-genome
sequencing association study of inflammatory bowel disease in 4,280 European affected individuals,14 we find little evidence for large effect rare variants explaining much
of the heritability. We did observe an aggregate association of rare, likely deleterious variants at CALB2 with ulcerative colitis, and many variants were specific to African
populations (absent in European [non-Finnish] populations in gnomAD). However, though it exceeded exomewide significance, this finding needs to be interpreted
with caution because of the lack of replication in an independent cohort or functional validation. Our study assesses rare variant contributions to inflammatory bowel
diseases in African Americans and will need evidence
from future studies to further support the association at
CALB2 with ulcerative colitis. Nevertheless, our study
highlights that multiple rare variants with small to moderate effects exist, and at least, when clustered in a small
number of sets (genes, windows etc.), are likely to account
for some of the missing heritability. However, much
larger-scale, deep-sequencing studies will be needed to
precisely estimate the variance in disease liability explained by such variants.
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Besides providing further evidence for the emerging
notion that the overall genetic risk of inflammatory bowel
disease conferred by common alleles is shared across populations, our data highlight the impact that subtle differences in the effect size and/or allele frequency can have
on the phenotype and the likelihood that rare variant contributions exert population-specific effects. Our effect size
estimates were based on univariate associations at lead
SNPs, an approach that most likely under-represents the
variance explained at each locus because it does not capture the effect of secondary associations that are modeled
by methods such as LD score regression.25 Since the
apparent proportion of the variance explained by a particular SNP is the sum of the effects of that SNP plus those in
LD (weighted by the extent of LD captured by the squared
genotype correlation), local differences in LD and rare
variant contributions will contribute to observed effect
size differences. However, interactions with the genetic
background as well as environmental/cultural differences,
including access to healthcare and the age distribution of
disease, all may also subtly contribute to variable allelic effects across populations. From the point of view of using
PRSs in practice, whether the cause of the difference is
due to main effects at the lead SNP or combined effects
of LD at neighboring SNPs is largely immaterial. It remains
to be seen whether such population-specific genetic contributions may provide insights into differences in diseases
incidence and progression across populations.
Our analyses also provide an example of how polygenic
analysis needs to be adjusted for ancestry when considering ethnic disparities in health care. It is well established
that frequency distributions of PRSs can differ markedly
across populations, mostly because of deviations in allele
frequencies,42–44 although ascertainment biases in discovery of common variant associations are also a concern.45
Fine-scale mapping of diverse clinical, behavioral, and hematological traits in large multi-ethnic cohorts such as
PAGE and BioME has been shown to identify new loci,
resolve secondary signals, and quantify divergent allelic effects46,47 despite high overall levels of repeatability, consistent with our observations. Admixture mapping has also
been used to refine PRS estimation, for example producing
better discrimination in high risk percentiles for African
Americans with multiple myeloma.48 New methods for
incorporating such findings into polygenic prediction algorithms are rapidly emerging, notably those incorporating both local and global ancestry adjustments.49–51
Our findings similarly illustrate how observed risk distributions that differ across populations and as a function of the
discovery ancestry group can be used to improve risk
assessment. Optimal risk scores should combine genetic
and clinical features and will require better estimates based
on expanded sample collection within each ethnic background and in admixed populations.
It is not known to what extent the rank order of risk is
conserved in trans-ethnic risk assessment: if it is, then a
simple rescaling of the PRS distribution may suffice. How-

ever, we show, similar to a multi-ethnic comparison of
diabetes genetic risk,52 that incorporation of ancestry-specific weights significantly increases the inferred risk at the
upper tail of the polygenic risk distribution. This occurs
despite overall conservation of the average variance explained per locus accounting for compensation of
changes in allele frequency and allelic effect size. It is
striking that most of the gains in risk assessment occur
at the extreme tails of the PRS distribution. Our intuition
about this is that for most people, increases in effects at
some loci are offset by decreases at others, since the
magnitude and sign of the effects are generally uncorrelated. However, in the top and bottom percentiles, there
is an excess of alleles with the same sign of effect and
necessarily those individuals share more genotypes,
which establishes a large enough correlation of ancestryspecific estimates to enhance the PRS discrimination in
the correct population and add to the error in the incorrect one. Further research into the mechanisms responsible for ancestry-specific effects is warranted, including
evaluation of the influences of linked rare variants, cumulative genetic background modifiers, and genotype-byenvironment interactions.
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